retatrutide dosing schedule phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

It helps stimulate insulin secretion after meals, but a significant effect observed during its use for diabetes was weight loss, leading to its application in weight management

Diabetes (2001) 50:25407.10.2337/diabetes.50.11.2540 19 TongJPrigeonRLDavisHWBidlingmaierMKahnSECummingsDEet alGhrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans

GLP-1 medications have no abuse potential and no controlled substance designation

Preclinical studies have confirmed that GLP-1RAs can significantly reduce body fat accumulation and improve insulin sensitivity, which provides a new potential strategy for the treatment of sarcopenia [12]

Trials so far have shown superiority of GLP-1 receptor agonists and SGLT2 inhibitors in MACE reduction when compared to DPP-4 inhibitors